Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)
出版年份 2018 全文链接
标题
Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor)
作者
关键词
-
出版物
Cancers
Volume 10, Issue 6, Pages 157
出版商
MDPI AG
发表日期
2018-05-28
DOI
10.3390/cancers10060157
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAFV600E inhibitors
- (2018) TaeWon Kim et al. MOLECULAR CARCINOGENESIS
- ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
- (2018) Shujun Han et al. Nature Communications
- Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
- (2018) Luca Mologni et al. NEOPLASIA
- p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis
- (2017) Nicholas Theodosakis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells
- (2017) Mahamat Babagana et al. MOLECULAR CARCINOGENESIS
- Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood
- (2017) Julia Joung et al. NATURE
- Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma
- (2017) Megan C. Duggan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase
- (2017) Corinna Kosnopfel et al. Oncotarget
- Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
- (2017) R. Kefford et al. JOURNAL OF CLINICAL ONCOLOGY
- Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.
- (2017) W. H. Sharfman et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma
- (2016) Y. Qin et al. MOLECULAR CANCER THERAPEUTICS
- Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma
- (2016) Che-Hung Shen et al. NATURE MEDICINE
- Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
- (2016) F Faião-Flores et al. ONCOGENE
- High-resolution interrogation of functional elements in the noncoding genome
- (2016) N. E. Sanjana et al. SCIENCE
- Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells
- (2016) Lindsay C. Spender et al. Oncotarget
- A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib
- (2016) Tobias Sinnberg et al. EBioMedicine
- How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
- (2012) J. Wolchok ANNALS OF ONCOLOGY
- Therapy for metastatic melanoma: the past, present, and future
- (2012) Laura Finn et al. BMC Medicine
- Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
- (2012) Richard Wu et al. CANCER JOURNAL
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells
- (2012) Peng Hou et al. CELL CYCLE
- The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
- (2012) K. H. T. Paraiso et al. CLINICAL CANCER RESEARCH
- BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- Resistance patterns with tyrosine kinase inhibitors in melanoma
- (2012) Reinhard Dummer et al. CURRENT OPINION IN ONCOLOGY
- Radiation Therapy for Cutaneous Melanoma
- (2012) Christopher A. Barker et al. DERMATOLOGIC CLINICS
- Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma
- (2012) Vipin Yadav et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vemurafenib-induced neutrophilic panniculitis
- (2012) Jean-Benoît Monfort et al. MELANOMA RESEARCH
- Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
- (2012) J. Acquaviva et al. MOLECULAR CANCER THERAPEUTICS
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Infiltrating Lymphocytes in Melanoma
- (2012) Sylvia Lee et al. Current Oncology Reports
- Metformin Accelerates the Growth of BRAF V600E -Driven Melanoma by Upregulating VEGF-A
- (2012) Matthew J. Martin et al. Cancer Discovery
- Dendritic cell-based in vitro assays for vaccine immunogenicity
- (2012) Rob J. Vandebriel et al. Human Vaccines & Immunotherapeutics
- Adoptive Cell Therapy for Patients with Melanoma
- (2012) Mark E. Dudley Journal of Cancer
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy
- (2011) R. W. Joseph et al. CLINICAL CANCER RESEARCH
- Therapy for metastatic melanoma: an overview and update
- (2011) Glen M Boyle Expert Review of Anticancer Therapy
- Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
- (2011) Franziska Niehr et al. Journal of Translational Medicine
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Vemurafenib
- (2011) Keith. T Flaherty et al. NATURE REVIEWS DRUG DISCOVERY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
- (2011) C. Garbe et al. ONCOLOGIST
- Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents
- (2011) Evisabel A. Craig et al. Pigment Cell & Melanoma Research
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- New Therapeutic Options in the Medical Management of Advanced Melanoma
- (2011) Jose Lutzky SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Proteasome Inhibitor Bortezomib Sensitizes Melanoma Cells toward Adoptive CTL Attack
- (2010) J. M. Seeger et al. CANCER RESEARCH
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Targets of Raf in tumorigenesis
- (2010) T. S. Niault et al. CARCINOGENESIS
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth
- (2010) Alexander Roesch et al. CELL
- MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720
- (2010) C. C. Jiang et al. CLINICAL CANCER RESEARCH
- The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
- (2010) B. Comin-Anduix et al. CLINICAL CANCER RESEARCH
- Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib
- (2010) F Stegmeier et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
- (2010) Matthias Drosten et al. EMBO JOURNAL
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
- (2010) F M Kaplan et al. ONCOGENE
- Oncogenic RAF: a brief history of time
- (2010) David Solit et al. Pigment Cell & Melanoma Research
- PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
- (2010) John T. Lee et al. Pigment Cell & Melanoma Research
- PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells
- (2010) Ruth Halaban et al. Pigment Cell & Melanoma Research
- Advances in melanoma senescence and potential clinical application
- (2010) Sandy Giuliano et al. Pigment Cell & Melanoma Research
- Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS
- (2010) C C Jiang et al. Cell Death & Disease
- Integrating BRAF/MEK inhibitors into combination therapy for melanoma
- (2009) K S M Smalley et al. BRITISH JOURNAL OF CANCER
- Histone deacetylase inhibitors: Potential in cancer therapy
- (2009) P.A. Marks et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
- (2009) Emelie A. Djerf et al. MELANOMA RESEARCH
- Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model
- (2009) Debbie Liao et al. PLoS One
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ultrasound-Guided Aspiration and Corticosteroid Injection in the Management of a Paralabral Ganglion Cyst
- (2009) Neeti Bathia et al. PM&R
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
- (2008) Olaia Martínez-Iglesias et al. Clinical & Translational Oncology
- The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
- (2008) Angelo et al. Frontiers in Bioscience-Landmark
- OncogenicNRAShas multiple effects on the malignant phenotype of human melanoma cells culturedin vitro
- (2008) Malihe Eskandarpour et al. INTERNATIONAL JOURNAL OF CANCER
- Oncogenic B-RafV600EInhibits Apoptosis and Promotes ERK-dependent Inactivation of Bad and Bim
- (2008) Clare Sheridan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- Mutant B-RAF mediates resistance to anoikis via Bad and Bim
- (2008) K Boisvert-Adamo et al. ONCOGENE
- Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
- (2008) A. J. Frew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started